Regeneron Pharmaceuticals Cash Flow Statement
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Regeneron Pharmaceuticals free cash flow
In fiscal 2025, Regeneron Pharmaceuticals generated $4.98 billion of operating cash flow and spent $898.4 million on capital expenditures. That left free cash flow of $4.08 billion, a free-cash-flow margin of 28.4% of revenue. Free cash flow was up 11.3% from the prior year's $3.66 billion.
Regeneron Pharmaceuticals returned $3.81 billion to shareholders: $370.3 million in dividends and $3.44 billion in share repurchases, equal to 93% of free cash flow. Free cash flow covered dividend payments 11.0 times.
Summary generated from market data by MetaCap's automated system. Methodology
Regeneron Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 4.50B | 4.41B | 3.95B | 4.34B | 8.08B | 3.51B | 2.12B | 2.44B | 1.20B | 895.50M |
| Net Income growth (YoY) | +2.09% | +11.61% | -8.87% | -46.28% | +129.86% | +66.05% | -13.44% | +103.95% | +33.84% | +40.79% |
| Depreciation & Amortization | 543.70M | 482.90M | 421.00M | 341.40M | 286.20M | 235.90M | 210.30M | 148.20M | 145.50M | 104.70M |
| Stock-Based Compensation | 993.70M | 982.80M | 885.00M | 725.00M | 601.70M | 432.00M | 464.30M | 427.40M | 507.30M | 559.90M |
| Change in Working Capital | 532.60M | -618.30M | -94.10M | -243.30M | -1.92B | -1.50B | -200.50M | -697.00M | -926.50M | 240.80M |
| Operating Cash Flow | 4.98B | 4.42B | 4.59B | 5.01B | 7.08B | 2.62B | 2.43B | 2.20B | 1.31B | 1.49B |
| Capital Expenditures | -898.40M | -755.90M | -718.60M | -590.10M | -551.90M | -614.60M | -429.60M | -383.10M | -272.60M | -511.90M |
| Investing Cash Flow | -629.10M | -2.47B | -3.19B | -3.78B | -5.38B | -70.60M | -2.03B | -1.46B | -1.01B | -1.05B |
| Dividends Paid | -370.30M | 0 | 0 | — | — | — | — | — | — | — |
| Share Repurchases | -3.44B | -2.60B | -2.23B | -2.08B | -1.65B | -5.85B | -275.90M | -4.40M | 0 | 0 |
| Debt Issued | — | — | — | 0 | 0 | 1.98B | 0 | 0 | — | — |
| Debt Repaid | — | — | — | — | — | — | — | 0 | -19.90M | -32.80M |
| Financing Cash Flow | -3.72B | -2.20B | -1.79B | -1.01B | -1.01B | -1.97B | -252.10M | -77.10M | -24.40M | -700.50M |
| Net Change in Cash | 634.70M | -248.80M | -381.60M | 221.30M | 690.80M | 577.00M | 150.10M | 655.00M | 277.50M | -261.40M |
| Free Cash Flow | 4.08B | 3.66B | 3.88B | 4.42B | 6.53B | 2.00B | 2.00B | 1.81B | 1.03B | 974.00M |
This table shows 10 annual periods of Regeneron Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow REGN's reporting calendar. What is a cash flow statement?